Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating when Labcorp’s diagnostics volumes jump, or spotting CMS reimbursement risks buried in a footnote, usually means scrolling through hundreds of dense pages. Investors also juggle separate documents to track drug-development backlog, litigation updates, and Labcorp insider trading Form 4 transactions — a time-consuming process.
Stock Titan solves that problem. Our AI reviews every Labcorp quarterly earnings report 10-Q filing, flags segment revenue shifts, and delivers plain-English summaries within minutes. Need real-time alerts? We stream Labcorp Form 4 insider transactions real-time so you never miss an executive’s move. From Labcorp SEC filings explained simply to detailed Labcorp earnings report filing analysis, our tools answer natural questions such as “How to read Labcorp’s 10-K?” or “What did management disclose in the latest 8-K?”
Here’s what you can explore today:
- Labcorp annual report 10-K simplified – AI-powered breakdown of diagnostics vs. drug-development margins.
- Labcorp 8-K material events explained – instant context on acquisitions, subpoenas, or changes in payer policy.
- Labcorp executive stock transactions Form 4 – monitor patterns before earnings releases.
- Labcorp proxy statement executive compensation – compare leadership pay with testing-volume performance.
Whether you’re understanding Labcorp SEC documents with AI for compliance, or scanning trendlines for your next investment thesis, Stock Titan provides:
- AI-powered summaries that demystify accounting jargon
- Real-time EDGAR updates across all forms
- Expert insights into diagnostics pricing, payer mix, and backlog shifts
Stop hunting through PDFs and start making decisions with clarity.
Labcorp Holdings Inc. reported that its Board of Directors has appointed Victor Bulto as a new board member, effective December 1, 2025. He will receive director compensation consistent with Labcorp’s existing director compensation program described in its most recent proxy statement.
Bulto is President of Novartis U.S. and a member of the Novartis Executive Committee, roles he has held since April 2022. Over more than two decades at Novartis, he has led major therapeutic franchises and regional businesses, including U.S. Pharmaceuticals and European neuroscience. Labcorp later issued a press release announcing his appointment and filed it as an exhibit, highlighting his extensive pharmaceutical and leadership background.
Labcorp (LH) reported an insider transaction by President & CEO and Director Adam H. Schechter. On 11/11/2025, he sold 5,745 shares of common stock at $262.75 per share, as disclosed on Form 4.
The transaction was made pursuant to a Rule 10b5-1 trading plan. Following the sale, Schechter beneficially owns 87,574 shares, held directly.
Laboratory Corporation of America Holdings (LH) reported a Form 144 notice of a proposed sale of 5,745 common shares, with an aggregate market value of $1,509,498.75. The filing lists Fidelity Brokerage Services LLC as broker, an approximate sale date of 11/11/2025, and the NYSE as the exchange. Shares outstanding were 82,900,000.
The shares to be sold were acquired through restricted stock vesting on 02/02/2024 (1,911 shares), 02/07/2024 (2,101 shares), and 02/11/2024 (1,733 shares). The filing also shows a recent transaction by a named seller: Adam H. Schechter sold 5,643 shares on 08/11/2025 for $1,505,439.54 in gross proceeds.
Labcorp (LH) Form 4: EVP, President of Central Labs & International Megan D. Bailey reported equity transactions. On 11/01/2025, 370 shares of Common Stock were acquired (code M) from Restricted Stock Units. On 11/03/2025, 179 shares were surrendered (code F) at $257.84 to satisfy tax withholding.
Following these transactions, direct ownership stands at 3,594 Common Stock shares. Derivative holdings include 2,599 Restricted Stock Units that vest in three equal annual installments beginning on November 1, 2025.
Labcorp (LH) reported an insider equity update by EVP, CIO & CTO Akinbolade Oyegunwa. On 11/01/2025, 370 shares of common stock were acquired via the conversion of Restricted Stock Units (code M). On 11/03/2025, 107 shares were withheld to cover taxes at $257.84 per share (code F). Following these transactions, direct holdings are 3,727.253 shares.
The filing notes 1,939 Restricted Stock Units remain outstanding. These RSUs vest in three equal annual installments beginning on November 1, 2025.
Labcorp (LH) reported an insider transaction by Director Richelle P. Parham. On 10/31/2025, she executed a sale (Transaction Code S) of 7,009 shares of common stock at an average price of $254.2835 per share. Following the sale, she beneficially owns 2,469 shares, held directly.
The filing was signed by an attorney-in-fact on 11/04/2025.
LH filed a Form 144 notice for a proposed sale of 7,009 shares of common stock on the NYSE, with an approximate sale date of 10/31/2025. The filing lists an aggregate market value of $1,782,273.05 for the proposed sale and names Fidelity Brokerage Services LLC as broker. Shares outstanding were 82,900,000.
The shares to be sold were acquired through restricted stock vesting from 2018 through 2025, including tranches such as 1,263 (02/07/2018), 1,227 (02/12/2020), 986 (02/04/2021), 947 (02/07/2024), and 944 (02/06/2025), summing to 7,009 shares.
Labcorp Holdings Inc. reported stronger Q3 results. Revenue rose to $3,563.5 million from $3,282.0 million a year ago, and diluted EPS increased to $3.12 from $2.00 as operating income improved to $396.6 million. Diagnostics contributed about 78% of revenue and Biopharma Laboratory Services about 22%.
Year to date, revenue reached $10,435.9 million with net earnings attributable to Labcorp of $711.8 million. Cash from operations was strong at $1,026.3 million, supporting capital spending and portfolio moves. The company deployed $324.0 million on acquisitions and repurchased 0.9 million shares for $225.0 million at an average of $249.27. A quarterly dividend of $0.72 per share continued.
Balance sheet highlights show cash of $598.1 million, total assets of $18,261.6 million, and total debt of $5,582.4 million including the current portion. The accounts receivable securitization facility was increased to $700.0 million with $525.0 million outstanding. The company also announced agreements to acquire CHS outreach assets for approximately $195.0 million and Empire City Laboratories for up to $250.0 million, pending approvals.
FAQ
What is the current stock price of Labcorp Holdings (LH)?
What is the market cap of Labcorp Holdings (LH)?
